Table 3 Baseline BMD and change in BMD with 12-month tamoxifen therapy
Time point | All patients | Premenopausal | Postmenopausal | Previous chemotherapy | No chemotherapy |
---|---|---|---|---|---|
Lumbar spine | |||||
 Baseline (g cm−2) | 1.14 (1.12 to 1.16) | 1.17 (1.14 to 1.21)a | 1.13 (1.10 to 1.15)a | 1.14 (1.11 to 1.16) | 1.15 (1.12 to 1.18) |
 | n=262 | n=91 | n=171 | n=123 | n=139 |
 % Change at 12 months after tamoxifen | −0.9 (−1.6 to −0.2) | −2.4 (−3.6 to −1.2)b | −0.1 (−1.0 to 0.7)b | +0.5 (−0.5 to 1.5)d | −2.2 (−3.2 to−1.3)d |
 | n=218 | n=77 | n=141 | n=105 | n=113 |
Hip | |||||
 Baseline (g cm−2) | 0.99 (0.97 to 1.01) | 1.00 (0.97 to 1.03) | 0.98 (0.96 to 1.01) | 0.98 (0.96 to 1.00) | 1.00 (0.97 to 1.02) |
 | n=256 | n=90 | n=166 | n=120 | n=136 |
 % Change at 12 months after tamoxifen | 0.4 (−0.3 to 1.0) | −0.5 (−1.5 to 0.6)c | +0.9 (0.0 to 1.7)c | +1.3 (0.4 to 2.2)e | −0.5 (−1.5 to 0.4)e |
 | n=211 | n=78 | n=133 | n=103 | n=108 |